Table 1 Characteristics of the trials audited (n = 134) stratified by the presence of an internal pilot
| Â | Internal pilot | No internal pilot | Total | |
|---|---|---|---|---|
Disease area | Cancer | 14 (82.4%) | 3 (17.6%) | 17 |
Circulatory system | 6 (60.0%) | 4 (40.0%) | 10 | |
Digestive system | 1 (50.0%) | 1 (50.0%) | 2 | |
Ear, nose and throat | 1 (50.0%) | 1 (50.0%) | 2 | |
Eye diseases | 3 (75.0%) | 1 (25.0%) | 4 | |
Infections and infestations | 5 (100.0%) | 0 (0.0%) | 5 | |
Injury, occupational diseases, poisoning | 5 (71.4%) | 2 (28.6%) | 7 | |
Mental and behavioural disorders | 14 (60.9%) | 9 (39.1%) | 23 | |
Musculoskeletal diseases | 11 (84.6%) | 2 (15.4%) | 13 | |
Neonatal diseases | 2 (100.0%) | 0 (0.0%) | 2 | |
Nervous system diseases | 6 (66.7%) | 3 (33.3%) | 9 | |
Pregnancy and childbirth | 9 (60.0%) | 6 (40.0%) | 15 | |
Respiratory | 4 (80.0%) | 1 (20.0%) | 5 | |
Skin and connective tissue diseases | 3 (75.0%) | 1 (25.0%) | 4 | |
Urological and genital diseases | 6 (66.7%) | 3 (33.3%) | 9 | |
Othera | 7 (100.0%) | 0 (0.0%) | 7 | |
Power | 80% | 12 (66.7%) | 6 (33.3%) | 18 |
85% | 1 (100.0%) | 0 (0.0%) | 1 | |
90% | 75 (73.5%) | 27 (26.5%) | 102 | |
95% | 1 (50.0%) | 1 (50.0%) | 2 | |
Other | 8 (72.7%) | 3 (27.3%) | 11 | |
Year of funding decision | 2012 | 2 (28.6%) | 5 (71.4%) | 7 |
2013 | 29 (72.5%) | 11 (27.5%) | 40 | |
2014 | 20 (76.9%) | 6 (23.1%) | 26 | |
2015 | 20 (64.5%) | 11 (35.5%) | 31 | |
2016 | 26 (86.7%) | 4 (13.3%) | 30 | |